Global X Longevity Thematic
|
- Description
- Performance
- Comps
Fundamentals
Valuation
Rating
Global X Longevity Thematic ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the Indxx Global Longevity Thematic Index. |
Category | Global Equities |
Fund Sponsor | Global X |
Website | www.globalxfunds.com |
Inception date | May 10, 2016 |
Assets (mns) | $24 |
Currency | USD |
Expense ratio | 50 bp |
Distributions | Annually |
Regulation | Open-Ended Fund |
Custodian | |
Weighting | Market Cap |
Index replication | |
Uses derivatives | No |
Options available | No |
No. of constituents | 98 |
Wgt avg mkt cap (mns) | $45,863 |
Large cap (>$10bn) | 76.6% |
Mid cap ($2-10bn) | 16.8% |
Small cap (<$2bn) | 5.6% |
Developed mkts | 98.1% |
Emerging mkts | 1.9% |
CHUGAI PHARMACEUTICAL CO LTD | 4.0 % |
EDWARDS LIFESCIENCES CORP | 3.7 % |
MEDTRONIC PLC | 3.6 % |
BIOGEN IDEC INC | 3.6 % |
BRISTOL-MYERS SQUIBB CO | 3.6 % |
AMGEN INC | 3.4 % |
VERTEX PHARMACEUTICALS INC | 3.3 % |
BOSTON SCIENTIFIC CORP | 3.2 % |
NOVO NORDISK A/S-B | 3.1 % |
ABBVIE INC | 3.0 % | Total | 34.5 % |
---|
![]() |
UNITED STATES | 64.7 % |
![]() |
JAPAN | 7.5 % |
![]() |
DENMARK | 6.1 % |
![]() |
IRELAND | 4.3 % |
![]() |
BRITAIN | 3.0 % |
![]() |
SWITZERLAND | 2.5 % |
![]() |
FRANCE | 1.9 % |
![]() |
GERMANY | 1.9 % |
![]() |
SOUTH KOREA | 1.7 % |
![]() |
BELGIUM | 1.3 % |
HISTORICAL PERFORMANCE 

Custom date range | Compare to | ||
thru |
Year-to-date | 1 year | 5 years | 10 years | Since Incep. |
25.4% | 15.7% | -- | -- | 13.6% |
versus... | Beta | R-squared |
S&P500 | 0.94 | 61% |
MSCI EAFE | 0.85 | 42% |
MSCI Emg. Mkts. | 0.65 | 39% |
Recent close | $23.69 |
30d moving avg. | $23.03 |
Annualized volatility | 14.5% |
Short interest (ETF) | 1.0% |
Relative strength (RSI) | 70 |
Avg. volume (thou.) | 3 |
Turnover | 0.3% |
Bid/Ask (% of price) | 1.22% |
ADV underlying (mns) | $10,604 |
FINDING ALTERNATIVE FUNDS
Below is a list of 20 potential alternatives to the Global X Longevity Thematic ETF based on the alternatives' overlap in portfolio holdings with LNGR. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.
Benchmark ticker: | LNGR | Expense: | 50 bp | ALTAR Score™: | 3.3% |
Ticker | Fund Name |
Overlap1 vs LNGR (%) |
Expense ratio (bp) |
Savings vs LNGR (bp) |
ALTAR Score™ (%) |
ALTAR vs LNGR (%) |
RYH | Invesco S&P Equal Weight Healthcare | 29.1 | 40 | 10 | 7.0 | +3.7 |
IYH | iShares US Healthcare | 29.0 | 43 | 7 | 6.3 | +2.9 |
FHLC | Fidelity MSCI Health Care | 28.2 | 8 | 42 | 5.8 | +2.5 |
GDNA | Goldman Sachs Motif Human Evolution | 27.4 | 50 | 0 | 1.0 | -2.3 |
XLV | Health Care Select Sector SPDR | 27.4 | 13 | 37 | 7.2 | +3.9 |
VHT | Vanguard Health Care | 27.0 | 10 | 40 | 5.9 | +2.6 |
IEIH | iShares Evolved U.S. Innovative Healthcare | 26.2 | 18 | 32 | 4.4 | +1.1 |
JHMH | John Hancock Multifactor Health Care | 26.1 | 40 | 10 | 6.6 | +3.3 |
IHI | iShares DJ US Medical Devices | 25.2 | 43 | 7 | 3.8 | +0.5 |
IEHS | iShares Evolved U.S. Healthcare Staples | 24.8 | 18 | 32 | 5.9 | +2.6 |
IBB | iShares NASDAQ Biotechnology | 23.2 | 47 | 3 | 0.4 | -2.9 |
IXJ | iShares S&P Global Healthcare | 23.1 | 46 | 4 | 6.4 | +3.0 |
FXH | First Trust Health Care Alphadex | 21.9 | 63 | -13 | 7.1 | +3.7 |
HTEC | Robo Global Healthcare Technology and Innovation | 20.1 | 68 | -18 | -0.0 | -3.4 |
FBT | First Trust NYSE-ARCA Biotechnology | 19.7 | 57 | -7 | -0.7 | -4.1 |
XHE | SPDR S&P Health Care Equipment | 19.5 | 35 | 15 | 2.1 | -1.2 |
BBH | VanEck Vectors Biotech | 19.2 | 35 | 15 | 4.5 | +1.2 |
XBI | SPDR S&P Biotech ETF | 18.6 | 35 | 15 | -4.4 | -7.8 |
BBP | BioShares Biotech Products | 16.0 | 79 | -29 | -3.7 | -7.0 |
PJP | Invesco Dynamic Pharmaceuticals | 16.0 | 56 | -6 | 9.4 | +6.1 |
1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.
Content on this tab for subscribers only**
RESULTS & ESTIMATES
2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | |
---|---|---|---|---|---|---|---|
Sales per share | ** | ** | ** | ** | ** | ** | ** |
Earnings per share | ** | ** | ** | ** | ** | ** | ** |
Dividends per share ![]() |
** | ** | ** | ** | ** | ** | ** |
Book value per share | ** | ** | ** | ** | ** | ** | ** |
Sales per share growth | **% | **% | **% | **% | **% | **% | |
EPS growth | **% | **% | **% | **% | **% | **% |
Sales per share growth | **% | **% | **% | **% | **% | **% | |
EPS growth | **% | **% | **% | **% | **% | **% |
OTHER FUNDAMENTAL METRICS
Long term EPS growth est. | **% | Debt-to-equity | **x | |
Asset turnover | **% | Assets-to-equity | **x |
*Six months ago = 100 |
Content on this tab for subscribers only
VALUATION METRICS
2018 | 2019E | 2020E | |
---|---|---|---|
Price-to-sales | ** | ** | ** |
Price-to-earnings | ** | ** | ** |
Price-to-cash flow | ** | ** | ** |
Price-to-growth | ** | ** | ** |
Price-to-book value | ** | ** | ** |
Yield | ** | ** | ** |
Historical valuation trends
Forward multiple: |
Global X Longevity Thematic | |||
Relative to: |
S&P500 | MSCI EAFE | MSCI Emg. Mkts. | Other ETF: |
UNDERWEIGHT |
Below average appreciation potential. A rating of UNDERWEIGHT is assigned to ETFs with ALTAR Scores in the 2nd quintile (ranking higher than only 20%-40%) of their category. Typically, funds in this category consist of stocks trading at relatively expensive valuations and/or having below-average fundamentals. |
ALTAR Score™
|
MODERN PORTFOLIO THEORY
![]() |
CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
|